Neovasc Inc(NVCN) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. The company is headquartered in Richmond British Columbia, British Columbia and currently employs 98 full-time employees. The firm develops, manufactures and markets products for the cardiovascular marketplace. The firm's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.

Current Price

$0.86

RSI

41.506

Beta:

2.846204

September 30, 2020
10.2M
-9.1M

25.159 %
25.276 %
-64.611 %
-8.579 %

$2,092,032
$1,749,133
$5,389,014
$9,512,796
$9,929,940
$13,665,258
19.604 %
-208.096 %
-76.522 %
-4.385 %
-37.617 %

$-35,102,222
$-107,935,775
$-22,424,293
$-86,294,370
$-26,563,140
$-16,419,808
207.490 %
-79.224 %
284.825 %
-69.218 %
-38.186 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.